- Q3 2025 sales decreased by 3% in local currencies to CHF 906 million.
- 9M 2025 sales decreased by 1% in local currencies to CHF 2.887 billion.
- CHF 80 million Investor Day savings program is on track with CHF 31 million achieved year-to-date.
- 2025 outlook: local currency sales growth at 1-3%, EBITDA margin 17-18%.
Sales Performance
In Q3 2025, Clariant's sales decreased by 3% in local currencies, totaling CHF 906 million. This decline was due to lower sales in Care Chemicals and Catalysts, despite modest growth in Adsorbents & Additives. For the first nine months of 2025, sales fell by 1% in local currencies to CHF 2.887 billion, primarily driven by reduced volumes.
EBITDA Margin Improvement
Clariant's Q3 2025 EBITDA margin before exceptional items rose by 230 basis points to 17.9%, up from 15.6% in Q3 2024. This improvement was attributed to performance enhancement programs and effective price and cost management across all business units. For the first nine months of 2025, the EBITDA margin increased by 160 basis points to 18.0% from the previous year's 16.4%.
Cost Savings Initiative
The CHF 80 million Investor Day savings program is progressing well, with CHF 31 million in savings achieved year-to-date. This initiative is part of Clariant's broader strategy to enhance operational efficiency and profitability.
2025 Outlook
Clariant has confirmed its 2025 outlook, expecting local currency sales growth at the lower end of the 1-3% range. The company also anticipates an EBITDA margin before exceptional items between 17-18%, as it navigates a challenging industrial production outlook and consumer sentiment.
